Frequencies of eGFP+ and FO B cells in the spleen of irf4floxedCD20-TAM-Cre mice 72 h after α-NRR2 treatment
| Genotype | Treatment | % eGFP+CD19+ cells | % FO (among CD19+ cells) | % eGFP+ B cells (among FO) |
| irf4fl/+CD20-TAM-Cre | IgG (n = 4) | 51.4 ± 2.6 | 76.4 ± 3.6 | 54.9 ± 2.9 |
| α-NRR2 (n = 4) | 44.0 ± 6.0 | 88.1 ± 3.0 | 48.3 ± 5.8 | |
| irf4fl/flCD20-TAM-Cre | IgG (n = 4) | 59.1 ± 11.7 | 73.9 ± 5.2 | 62.0 ± 10.4 |
| α-NRR2 (n = 4) | 49.6 ± 4.8 | 85.3 ± 3.0 | 55.4 ± 4.8 |
| Genotype | Treatment | % eGFP+CD19+ cells | % FO (among CD19+ cells) | % eGFP+ B cells (among FO) |
| irf4fl/+CD20-TAM-Cre | IgG (n = 4) | 51.4 ± 2.6 | 76.4 ± 3.6 | 54.9 ± 2.9 |
| α-NRR2 (n = 4) | 44.0 ± 6.0 | 88.1 ± 3.0 | 48.3 ± 5.8 | |
| irf4fl/flCD20-TAM-Cre | IgG (n = 4) | 59.1 ± 11.7 | 73.9 ± 5.2 | 62.0 ± 10.4 |
| α-NRR2 (n = 4) | 49.6 ± 4.8 | 85.3 ± 3.0 | 55.4 ± 4.8 |